In preclinical studies, TNFR2 antibody therapy has shown effectiveness either alone or in combination with classical PD-1/CTLA-4 antibodies as it suppresses colorectal cancer and augments the efficacy of anti-PD1 immunotherapy by blocking TNF- α/TNFR2 signaling and decreasing CCR8+T regulatory cells (66, 78). Here, TNFRSF1B is linked to colorectal cancer.